Research programme: herpes simplex vaccine - Immune Design

Drug Profile

Research programme: herpes simplex vaccine - Immune Design

Alternative Names: G103; Herpes symplex virus 2 vaccine - Immune Design; HSV therapeutic vaccine - Immune Design; HSV2 vaccine + GLA - Immune Design; IDC-G103

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Herpes simplex virus type 2 infections

Most Recent Events

  • 17 Aug 2016 IDC G103 is still in preclinical development for Herpes simplex virus type-2 infections in USA (Immune Design pipeline, August 2016; Immune Design 10-Q, April 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA
  • 16 Oct 2014 Sanofi Pasteur and Immune Design Corporation enter into a broad collaboration to develop HSV immunotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top